Canaccord Genuity Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)

In a report released today, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Taysha Gene Therapies, with a price target of $14.00. The company’s shares closed yesterday at $5.00.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Ijem is a 5-star analyst with an average return of 31.7% and a 57.38% success rate. Ijem covers the Healthcare sector, focusing on stocks such as Wave Life Sciences, Rhythm Pharmaceuticals, and Rocket Pharmaceuticals.

In addition to Canaccord Genuity, Taysha Gene Therapies also received a Buy from Truist Financial’s Joon Lee in a report issued on October 3. However, on the same day, TR | OpenAI – 4o reiterated a Hold rating on Taysha Gene Therapies (NASDAQ: TSHA).

Based on Taysha Gene Therapies’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.99 million and a GAAP net loss of $26.88 million. In comparison, last year the company earned a revenue of $1.11 million and had a GAAP net loss of $20.93 million

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TSHA in relation to earlier this year. Most recently, in August 2025, Sukumar Nagendran, the President and Head of R&D of TSHA sold 57,054.00 shares for a total of $162,603.90.